Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Cash from Investing Activities (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Cash from Investing Activities for 15 consecutive years, with -$17000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Investing Activities fell 111.72% to -$17000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$3.1 million, a 794.18% decrease, with the full-year FY2025 number at -$2.6 million, down 678.12% from a year prior.
  • Cash from Investing Activities was -$17000.0 for Q4 2025 at Aytu Biopharma, up from -$3.0 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $381000.0 in Q3 2024 to a low of -$3.1 million in Q4 2021.
  • A 5-year average of -$483166.7 and a median of -$57000.0 in 2024 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: tumbled 10070.0% in 2021, then surged 601.32% in 2024.
  • Aytu Biopharma's Cash from Investing Activities stood at -$3.1 million in 2021, then surged by 99.84% to -$5000.0 in 2022, then crashed by 3380.0% to -$174000.0 in 2023, then skyrocketed by 183.33% to $145000.0 in 2024, then crashed by 111.72% to -$17000.0 in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Cash from Investing Activities are -$17000.0 (Q4 2025), -$3.0 million (Q2 2025), and -$69000.0 (Q1 2025).